These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10326421)

  • 1. The interrelation between renal and cardiac function. Physiology and pathophysiology with a focus on congestive heart failure.
    Stark J
    Crit Care Nurs Clin North Am; 1998 Dec; 10(4):411-9. PubMed ID: 10326421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal mechanisms in heart failure.
    Birkenhäger WH; de Leeuw PW
    Herz; 1991 Apr; 16(2):61-7. PubMed ID: 2066054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney function in congestive heart failure.
    Williams AV
    J S C Med Assoc; 1994 Dec; 90(12):579-85. PubMed ID: 7869694
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical interactions of the heart, cardiovascular system and kidney].
    Erdmann E; von Scheidt W; Böhm M; Kemkes B
    Verh Dtsch Ges Inn Med; 1989; 95():24-33. PubMed ID: 2690493
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
    Blankstein R; Bakris GL
    Heart Fail Clin; 2008 Oct; 4(4):425-38. PubMed ID: 18760754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
    Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
    J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Central hemodynamics, kidney functions and water-salt metabolism in patients with ischemic heart disease and an increased venous blood return to the heart].
    Synchuk AN; Biletskiĭ SV; Kravchenko VA; Rozgon GI; Voevidka KP; Glibka AZ; Dovganiuk NI; Bobylev AV
    Vrach Delo; 1991 Jan; (1):57-9. PubMed ID: 2011895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'.
    Riley DJ; Weir M; Bakris GL
    Postgrad Med; 1994 Jun; 95(8):153-6. PubMed ID: 8202420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
    Rademaker MT; Charles CJ; Cooper GJ; Coy DH; Espiner EA; Lewis LK; Nicholls MG; Richards AM
    Clin Sci (Lond); 2002 Jun; 102(6):653-60. PubMed ID: 12049620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure.
    Sami M
    Can J Cardiol; 1999 May; 15 Suppl C():19C-23C. PubMed ID: 10380688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From digoxin to angiotensin-converting enzyme inhibitors: issues in pharmacotherapy for congestive heart failure.
    Hackenbruck HA
    Clin Excell Nurse Pract; 2000 Jul; 4(4):197-204. PubMed ID: 11261079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I; Rubonivich S; Azaz-Livshits T
    Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High output heart failure.
    Mehta PA; Dubrey SW
    QJM; 2009 Apr; 102(4):235-41. PubMed ID: 18990720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute renal insufficiency due to vomiting or diarrhea: the Achilles heel of medical support for heart failure].
    Jacobs EM; van Leusen R; Bosch FH
    Ned Tijdschr Geneeskd; 2000 Sep; 144(38):1817-20. PubMed ID: 11020833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalemia risk and treatment of heart failure.
    Segura J; Ruilope LM
    Heart Fail Clin; 2008 Oct; 4(4):455-64. PubMed ID: 18760757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of chronic heart failure in patients with chronic kidney disease.
    Zachariah D; Kalra PA; Kalra PR
    J Ren Care; 2009 Mar; 35(1):2-10. PubMed ID: 19200271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading.
    Tomiyama H; Watanabe G; Abe M; Okazaki R; Yoshida H; Doba N
    Am Heart J; 2001 Mar; 141(3):422-7. PubMed ID: 11231440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.